Most cases of FCS — around 80% — are attributed to mutations (changes) of the LPL gene. Your LPL gene contains the instructions for making an enzyme called lipoprotein lipase (LPL), which your ...
GC304: Genecradle Therapeutics GC304 adeno-associated virus injection is a recombinant AAV viral vector carrying the LPL gene expression cassette. LPL is a key enzyme in the human body for ...
Another European gene therapy company, Amsterdam Molecular Therapeutics (AMT) of Amsterdam, has filed a Marketing Authorization Application with EMEA for its lipoprotein lipase (LPL) deficiency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback